News Samsung Bioepis Herceptin biosimilar approved in EU Mylan and Biocon resolve biosimilar manufacturing issues
News Ready to pounce: Samsung joins Amgen with Humira biosimilar ... No-one can launch biosimilars until patent expires next year
News Samsung Bioepis signs R&D agreement with Takeda South Korean firm looking to develop novel drugs
News Regulators finally back Merck KGaA oral MS drug A long-awaited oral multiple sclerosis drug from Merck KGaA was among a raft of medicines given the green light by Europe's regulator on Friday.
News J&J's Remicade faces further biosimilar competition in US FDA approves Samsung Bioepis biosimilar.
News UK court overturns AbbVie Humira patents Decision paves way for cheaper competitor in autumn 2018.
R&D Reuters Pharma Europe 2024 – Peter Stenico Pioneering access to biosimilars is crucial for strengthening health equity by providing affordable, life-changing therapies to patients worldwide.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.